DRUG OF STUDY FOR COMPLETION OF RELATED LEARNING EXPERIENCE (RLE)

Student Name: Crizale Corpuz Duty Group: Emmaus Duty Area: Geria
(5C & 5D

Yr Level and BSN 3-Y1-5 Dates: Feb. 22, 23, 24 Clinical Instructor:
Section:

DRUG CLASSIFICATIO MECHANISM OF INDICATION CONTRAINDIC ADVERSE NURSING

N ACTION ATIONS EFFECTS RESPONSIBI
LITIES

PHARMACOTHE Therapeutic Effect: Clozapine is Caution: ● Agran

Generic RAPEUTIC: Linoleic acid is the indicated for ulocyto Serious
Name: Omega-6 fatty simplest omega-6 Clozapine is sis adverse
the treatment
Clozapine acids mediate fatty acid that can contraindicated ● Myoca effects that
of severely ill
pro- generate longer n- in patients with rditis require
patients with
Brand Name: inflammatory 6 polyunsaturated serious ● Metab monitoring
Clozaril,
schizophrenia olic
effects in the fatty acids such as hypersensitivity include but
Fazaclo, who fail to Syndro
cellular level eicosanoids, reactions to are not limited
Versacloz respond me
and compete for endocannabinoids clozapine or any to the
adequately to ● Seizur
the same rate- and lipoxins by the component of the following:
Dosage/ standard es
limiting insertion of formulation.
Route/ antipsychotic ● Exces Agranulocyto
Frequency: enzymes with additional double treatment. FDA states the sive sis: Weekly
Clozapine is omega-3 fatty bonds during following boxed Salivat complete
available as acids. consecutive warnings: ion blood count
oral tablets, Arachidonic elongation and ● Pulmo
(CBC) to
orally acid is desaturation nary
● Neutrope Emboli measure ANC
disintegrating converted to mechanisms. It levels. ANC
nia (due sm
tablets, and inflammatory gives rise to levels less
to the risk ● Consti
oral mediators such arachidonic acid pation than 1500 per
suspension in as omega-6 (AA) via γ-linolenic of
agranuloc ● Neurol mm indicate
the following prostaglandins acid (GLA, 18:3n-
strength. The and leukotriene 6) and dihomo-γ- eptic
choice of eicosanoids linolenic acid Malign neutropenia.
ytosis) ant Levels less
dosage form during the (DGLA, 20:3n-6)
● Orthostati Syndro than 500 per
depends on inflammatory and the same set
c me mm indicate
patient cascade. AA- of enzymes can
hypotensi agranulocytosi
acceptability derived also convert AA to
on, s. A complete
and eicosanoids are EPA and DHA.
bradycard blood count
tolerability. proinflammatory The initial rate
ia, and should be
but they have limiting
syncope taken weekly
important desaturation of LA
*Oral tablet ● Seizures for the first 6
homeostatic to GLA is
dosages of 25 ● Myocardi months, then
functions in catalysed by the
mg, 50 mg, tis and every other
regulating both enzyme delta-6-
100 mg, and mitral week for the
the promotion desaturase
200 mg valve next 6 months.
and resolution (FADS2) and
incompet A national
of inflammation elongation of GLA
ence registry is in
*Orally in the immune to DGLA by delta-
● Increased place to
disintegrating response. It is 5-desaturase
mortality monitor for
tablet dosages reported that (FADS1)
in safe use.
of 12.5 mg, 25 high intake of n- generates AA. AA
dementia-
mg, 100 mg, 6 PUFA, along is also converted Metabolic
related
150 mg, and with low intakes to 2-series syndrome:
psychosis
200 mg of n-3 PUFA, prostaglandins Diet and
in elderly
shifts the (PGD2, PGE2, exercise,
patients
*Oral physiological PGF2, PGI2) blood glucose
(risk of a
suspension state to one that andthromboxanes levels.
cardiovas
dosage of 50 is (TXA2, TXB2) by
cular Cardiovascul
mg/mL (100 proinflammatory COX-2 activity and
event) ar: Baseline
mL) and 4-series
prothrombotic leukotrienes troponin I or T
with increases (LTA4, LTB4, levels, high
Adult Dosing in vasospasm, LTC4, LTD4, sensitivity
vasoconstriction LTE4) by 5-LOX CRP levels,
 , and blood activity. Resulting
viscosity and lipid signalling echocardiogra
*Treatment- phy, and BNP
the molecules have
resistant levels, as well
development of various pro-
schizophrenia as vitals and
diseases inflammatory
and weekly
associated with effects on target
schizophrenia- laboratory
these tissues and cells;
associated testing of
conditions. Thus bronchostriction,
suicide troponins,
maintaining the fever, pain,
prevention - CRP, and
balance increased
150 to 300 mg BNP levels.
between 2 production of
orally twice
polyunsaturated inflammatory Seizure: EEG
daily. Start
fatty acids is cytokines such as and clozapine
12.5 mg daily
critical in TNF-alpha and IL- blood levels
or twice daily,
inflammatory 6, platelet
and increase Clinical
cascade aggregation,
by 25 to 50 monitoring:
regulation. vasoconstriction,
mg daily to Monitor for
vascular
target 300 to CLINICAL: clinical
permeability,
450 mg daily Antipsychotic improvement
chemotaxis of
in divided in patients at
leukocytes, and
doses by day each visit. The
release of reactive
14. Then, Clinical
oxygen species by
increase by up Global
granulocytes.
to 100 mg Impression–
Omega-6 fatty
daily every 3 Schizophrenia
acids activate
to 7 days. (CGI–SCH)
PPAR to the less
extent than scale can
Pediatric omega-3 fatty assess the
Dosing acids, but a study treatment
involving human response in
keratinocytes patients with
*Treatment-
showed induction
 of COX-2
expression schizophrenia.
resistant
resulting from
schizophrenia
PPAR-alpha
and
activation. Omega-
schizophrenia-
6 fatty acids are
associated
also reported to
suicide
directly activate
prevention -
syntaxin-3, a
125 to 475 mg
plasma protein
orally daily in
membrane that
2 or 3 divided
regulates vesicle
doses. Start
transport and
12.5 mg daily
growth of neurites.
or twice daily,
Absorption
and increase
Not Available
by 12.5 to 25
Volume of
mg daily
distribution
every 3 to 5
Not Available
days as
Protein binding
tolerated. The
Not Available
maximum
Metabolism
dose is 700
Most metabolism
mg daily. If
of polyunsaturated
divided doses
fatty acids occur in
are not equal,
the liver but may
give the larger
occur in other
dose at
tissues as well.
bedtime.
Metabolism of
omega-6 fatty
acids leads to
biosynthesis of
eicosanoids, as
mentioned above.
Linoleic acid can
be metabolized to
other more
unsaturated, long-
chain members of
the n-6 family by
the insertion of
additional double
bonds during
consecutive
elongation and
desaturation
mechanisms. The
initial rate limiting
desaturation of LA
to GLA is
catalysed by the
enzyme delta-6-
desaturase
(FADS2).
Elongation then
takes place to
convert GLA to
DGLA, by
elongation of very
long-chain fatty
acids (ELOVL) 5,
and finally a cycle
of elongation and
desaturation by
delta-5-desaturase
(FADS1)
generates AA